Clinical Trials Browser

Phase 2 × Breast Neoplasms, Male × Bevacizumab × Clear all

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00423917 2018-05-08

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

36 enrolled 11 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00662129 2017-04-17

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

50 enrolled 11 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00088998 2016-12-07

Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00119262 2014-05-15

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Phase 2 Completed

226 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00027885 2013-06-17

Phase II Bevacizumab + Tax In Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00017394 2013-01-17

Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male